AbbVie Stock News

Dividend Aristocrats are a rare group of stocks. Not only do these members of the S&P 500 pay shareholders a dividend but in order to make the cut, they need to have raised their payout at least yearl

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated dermatolog

Investors can effectively unlock financial freedom with dividend stocks to buy for a passive income stream. The key to invest in dividend stocks, promising a consistent and growing payout while offeri

AbbVie Inc. (NYSE:ABBV ) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 9:10 AM ET Company Participants Rob Michael - President, Chief Operating Officer and Incoming CEO Jeff Stewart -

Investing in dividend kings is about keeping things simple. A distinguishing feature of these companies is a rock-solid balance sheet that allows them to demonstrate unwavering commitment to building

In the most recent trading session, AbbVie (ABBV) closed at $178.91, indicating a +1.62% shift from the previous trading day.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

It's often said that patience is a virtue for investors that often means taking advantage of the stability of blue-chip stocks.   However, that virtue can be sorely lacking among investors.

Dividend growth stocks have consistently outshined most other asset classes over the past 124 years. AbbVie and Amgen are two of the brightest stars within the healthcare dividend growth stock landsca

NANTES, France--(BUSINESS WIRE)--OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership.

AbbVie is selling around $15 billion of bonds in the US investment-grade market to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics Holdings. Olivia Raimonde has more.

AbbVie is poised for growth just a couple of years after losing patent protection on its top-selling drug. Emerging products Skyrizi and Rinvoq have exceeded expectations.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

AbbVie Inc.'s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company's current president and chief operating officer, Robert Michael.